Payment overview · 2025
General Payments
$1,360.93
48 reported records · 17 companies
Healthcare provider profile · identity verified
Vipul M Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, TX · NPI 1700994613
Verified facts
What the public records show
CMS Open Payments records show Vipul M Patel, MD received $1,360.93 in general payments during 2025 across 48 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $383.91 | 28.2% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $357.27 | 26.2% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.56 | 5.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.15 | 4.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.60 | 4.7% | 4 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $62.73 | 4.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.33 | 4.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.40 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.94 | 3.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $41.54 | 3.0% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $27.65 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.62 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.12 | 1.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.79 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.30 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.18 | 1.3% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $17.84 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,360.93 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $383.91 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $202.08 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.79 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.18 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $81.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $78.56 | 3 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $62.73 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $62.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $62.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $62.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.33 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.16 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.11 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 192 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 184 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
192 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
139 | 44 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
184 | 49 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1650 | 478 |
| Levothyroxine Sodium | Levothyroxine Sodium | 771 | 190 |
| Gabapentin | Gabapentin | 735 | 250 |
| Losartan Potassium | Losartan Potassium | 706 | 217 |
| Metformin Hcl | Metformin Hcl | 652 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 184 |
| Lisinopril | Lisinopril | 567 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 542 | 179 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 507 | 192 |
| Furosemide | Furosemide | 488 | 146 |
| Meloxicam | Meloxicam | 473 | 156 |
| Metoprolol Succinate | Metoprolol Succinate | 425 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 357 | 117 |
| Omeprazole | Omeprazole | 353 | 125 |
| Tizanidine Hcl | Tizanidine Hcl | 305 | 132 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 102 |
| Alendronate Sodium | Alendronate Sodium | 266 | 83 |
| Tramadol Hcl | Tramadol Hcl | 264 | 83 |
| Glimepiride | Glimepiride | 237 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 236 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 219 | 59 |
| Montelukast Sodium | Montelukast Sodium | 206 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 203 | 108 |
| Eliquis | Apixaban | 198 | 51 |
| Ezetimibe | Ezetimibe | 198 | 68 |
| Carvedilol | Carvedilol | 192 | 65 |
| Farxiga | Dapagliflozin Propanediol | 192 | 63 |
| Clonidine Hcl | Clonidine Hcl | 190 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 58 |
| Trazodone Hcl | Trazodone Hcl | 190 | 56 |
| Folic Acid | Folic Acid | 185 | 86 |
| Ozempic | Semaglutide | 184 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 176 | 87 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 166 | 118 |
| Sertraline Hcl | Sertraline Hcl | 166 | 54 |
| Spironolactone | Spironolactone | 147 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 29 |
| Allopurinol | Allopurinol | 142 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 44 |
| Clonazepam | Clonazepam | 135 | 37 |
| Potassium Chloride | Potassium Chloride | 134 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 42 |
| Mupirocin | Mupirocin | 120 | 85 |
| Cephalexin | Cephalexin | 119 | 96 |
| Mirtazapine | Mirtazapine | 118 | 47 |
| Azithromycin | Azithromycin | 113 | 93 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 49 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 67 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 106 | 41 |
| Finasteride | Finasteride | 106 | 40 |
| Ibuprofen | Ibuprofen | 104 | 41 |
| Jardiance | Empagliflozin | 103 | 34 |
| Meclizine Hcl | Meclizine Hcl | 103 | 42 |
| Metformin Hcl Er | Metformin Hcl | 102 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 100 | 55 |
| Naproxen | Naproxen | 99 | 46 |
| Sucralfate | Sucralfate | 96 | 46 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 23 |
| Prednisone | Prednisone | 92 | 44 |
| Enalapril Maleate | Enalapril Maleate | 87 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 87 | 22 |
| Pregabalin | Pregabalin | 86 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 27 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 80 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 78 | 19 |
| Famotidine | Famotidine | 78 | 34 |
| Atenolol | Atenolol | 77 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 21 |
| Valsartan | Valsartan | 76 | 19 |
| Lactulose | Lactulose | 71 | 43 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 31 |
| Pentoxifylline | Pentoxifylline | 68 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 67 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 53 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Entresto | Sacubitril/Valsartan | 61 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 22 |
| Cilostazol | Cilostazol | 60 | 25 |
| Donepezil Hcl | Donepezil Hcl | 60 | 11 |
| Nifedipine Er | Nifedipine | 60 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 60 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 45 |
| Digoxin | Digoxin | 57 | suppressed |
| Glipizide | Glipizide | 56 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 56 | 47 |
| Clotrimazole | Clotrimazole | 53 | 27 |
| Methylprednisolone | Methylprednisolone | 53 | 42 |
| Tradjenta | Linagliptin | 53 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 49 | 20 |
| Bupropion Xl | Bupropion Hcl | 47 | 12 |
| Celecoxib | Celecoxib | 47 | 20 |
| Levetiracetam | Levetiracetam | 47 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 42 | 12 |
| Lidocaine | Lidocaine | 41 | 13 |
| Nitroglycerin | Nitroglycerin | 41 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 18 |
| Januvia | Sitagliptin Phosphate | 38 | 13 |
| Buspirone Hcl | Buspirone Hcl | 36 | 12 |
| Cromolyn Sodium | Cromolyn Sodium | 36 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 24 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Ofloxacin | Ofloxacin | 33 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Primidone | Primidone | 33 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 15 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 15 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 26 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | 12 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | 13 |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Linzess | Linaclotide | 23 | 14 |
| Metronidazole | Metronidazole | 23 | 19 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 22 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | 14 |
| Latanoprost | Latanoprost | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 17 | 15 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | 11 |
| Methimazole | Methimazole | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 13 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,360.93 · 48 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, AJOVY, AREXVY, BRAFTOVI, BREZTRI, CHARTIS CATHETER, Cologuard Collection Kit, FARXIGA, Fluad, Flucelvax, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, MEKTOVI, NEXLETOL, Ozempic, PULMONX CHARTIS TABLET CONSOLE, REZDIFFRA, SAPHNELO, SHINGRIX, TRELEGY ELLIPTA, TUKYSA, TZIELD, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error